PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma

E. Taniguchi, K. Nishijo, A. T. McCleish, J. E. Michalek, M. H. Grayson, A. J. Infante, H. E. Abboud, R. D. Legallo, S. J. Qualman, B. P. Rubin, C. Keller

Producción científica: Articlerevisión exhaustiva

83 Citas (Scopus)

Resumen

Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood. Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. Using our conditional mouse tumor models that authentically recapitulate the primary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting and immunokinase assays that PDGFR-A and its downstream effectors, mitogen-activated protein kinase and Akt, were highly activated in both primary and metastatic tumors. Inhibition of PDGFR-A by RNA interference, small molecule inhibitor or neutralizing antibody had a dramatic effect on tumor cell growth both in vitro and in vivo, although resistance evolved in one-third of tumors. These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.

Idioma originalEnglish (US)
Páginas (desde-hasta)6550-6560
Número de páginas11
PublicaciónOncogene
Volumen27
N.º51
DOI
EstadoPublished - oct 30 2008

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma'. En conjunto forman una huella única.

Citar esto